Association of Toll-like receptor 10 and susceptibility to Crohn's disease independent of NOD2

Genes and Immunity

Volumn 12, Issue 8, 2011, Pages 635-642

  Abad, C ^a   Gonzalez Escribano M F ^a   Diaz Gallo, L M ^d   Lucena Soto, J M ^a   Marquez J L ^b   Leo, E ^b   Crivell, C ^b   Gomez Garcia M ^c   Martin J ^d   Nez Roldan A ^a   Garcia Lozano J R ^a  

^a Instituto de Biomedicina de Sevilla   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Crohn's disease; gene gene interactions; genetic association; NOD2 CARD15 gene; TLR10 gene; Toll like receptors

Indexed keywords

MESSENGER RNA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 6;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; ENDOSOME; ENTROPY; FEMALE; GENE CLUSTER; GENE INTERACTION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIFACTOR DIMENSIONALITY REDUCTION; PRIORITY JOURNAL; REDUNDANCY ANALYSIS; RNA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ALLELES; CASE-CONTROL STUDIES; CHILD; CROHN DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 10; TOLL-LIKE RECEPTOR 6; YOUNG ADULT;

EID: 82555189795     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2011.41     Document Type: Article

References (36)

1. Abreu MT, Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. J Pediatr 2004; 144: 421-429. (Pubitemid 38457342)
2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-533. (Pubitemid 37328672)
3. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006; 367: 668-678. (Pubitemid 43289157)
4. Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NODlike receptors in host defense and disease. Immunity 2007; 27: 549-559. (Pubitemid 47615512)
5. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-8872. (Pubitemid 36800360)
6. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603. (Pubitemid 32531408)
7. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002; 123: 86-91. (Pubitemid 34747528)
8. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P. European Collaborative Study Group on Inflammatory Bowel Disease. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel 2007; 13: 24-32. (Pubitemid 46080006)
9. Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005; 11: 645-652. (Pubitemid 40965520)
10. Török HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004; 127: 365-366. (Pubitemid 38962306)
11. Török HP, Glas J, Endres I, Tonenchi L, Teshome MY, Wetzke M et al. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009; 104: 1723-1733.
12. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801. (Pubitemid 43261452)
13. Chuang T, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 2001; 1518: 157-161. (Pubitemid 32232289)
14. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97: 13766-13771.
15. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, Guiet C, Brière F, Vlach J, Lebecque S, Trinchieri G, Bates EE. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005; 174: 2942-2950. (Pubitemid 40279713)
16. Tantisira K, Klimecki WT, Lazarus R, Palmer LJ, Raby BA, Kwiatkowski DJ et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004; 5: 343-346. (Pubitemid 39139760)
17. Lazarus R, Raby BA, Lange C, Silverman EK, Kwiatkowski DJ, Vercelli D et al. TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med 2004; 170: 594-600. (Pubitemid 39202199)
18. Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97: 525-532. (Pubitemid 40590434)
19. Zhou XX, Jia WH, Shen GP, Qin HD, Yu XJ, Chen LZ et al. Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 862-866.
20. Purdue MP, Lan Q, Wang SS, Kricker A, Menashe I, Zheng TZ et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009; 30: 275-281.
21. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1-and TLR2-deficient mice. Nat Med 2002; 8: 878-884.
22. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-1161. (Pubitemid 34225814)
23. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962.
24. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad Tet al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.
25. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147. (Pubitemid 32614026)
26. Moore JH. Computational analysis of gene-gene interactions using multifactor dimensionality reduction. Expert Rev Mol Diagn 2004; 4: 795-803. (Pubitemid 39487584)
27. Moore JH, Wllimas SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. BioEssays 2005; 27: 637-646. (Pubitemid 40896095)
28. Murray PJ. Beyond peptidoglycan for Nod2. Nat Immunol 2009; 10: 1053-1054.
29. van Heel DA, Ghosh S, Hunt KA, Mathew CG, Forbes A, Jewell DP, Playford RJ. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut 2005; 54: 1553-1557. (Pubitemid 41531770)
30. Guan Y, Ranoa DR, Jiang S, Mutha SK, Li X, Baudry J, Tapping RI. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol 2010; 184: 5094-5103.
31. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753. (Pubitemid 43764536)
32. Becker T, Knapp M. Maximum-likelihood estimation of haplotype frequencies in nuclear families. Genet Epidemiol 2004; 27: 21-32. (Pubitemid 38808342)
33. Garćia-Lozano JR, Torres B, Fernández O, Orozco G, Alvarez-Márquez A, Garćia A et al. Caspase 7 influences susceptibility to rheumatoid arthritis. Rheumatology 2007; 46: 1243-1247. (Pubitemid 47244493)
34. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-723.
35. Epstein MP, Satten GA. Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 2003; 73: 1316-1329. (Pubitemid 38037425)
36. Jakulin A, Bratko I. Analyzing attribute depedencies. In: Lavrac N, Gamberger D, Blockeel H, Todorovski L, (eds). PKDD 2003. Cavtat Croatia: Springer-Verlag, 2003, pp 229-240.